Jennifer Barrett, Associate Editor

Despite the completion of CVS Health’s purchase of Aetna in November, the company continues to be challenged over the merger’s potentially harmful effect on consumers and smaller competitors.

Two pharmacist groups jointly filed a motion urging the federal judge to block CVS and Aetna from further integration while the potential negative effects are assessed.

Slow-growing gliomas in patients with neurofibromatosis type 1 may be vulnerable to immunotherapy.

Officials with the FDA have approved romiplostim (NPLATE, Amgen) for the treatment of immune thrombocytopenia (ITP) in pediatric patients aged 1 year and older.

Romiplostim (NPLATE, Amgen) approved for the treatment of pediatric patients with immune thrombocytopenia who have had an insufficient response to other therapies.

Updated data from the HAVEN 2 study showed that the majority of children treated with emiciziumab-kxwh (Hemlibra, Genentech) experienced sustained bleed control.

For men living with HIV, stigma associated with the disease may be directly related to cognitive impairment and everyday functioning

Understanding how HIV-related stigma can affect patients later in life can lead to new approaches to address cognitive impairment in this population.

New study data reinforce the long-term efficacy and safety of Amgen’s evolocumab (Repatha) in individuals at risk for heart attack and stroke, but an additional analysis highlights challenges associated with use of lipid-lowering therapies (LLTs) in these patients.

Study shows that routinely screening inmates for hepatitis C virus at entry may identify a significant number of cases that would have been missed through targeted testing.

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.

Two phase 3 studies evaluating the triple combination regimen met the primary endpoint of improvement in lung function in patients with at least 1 F508del mutation.

Evolocumab (Repatha) consistently reduced low-density lipoprotein cholesterol in high-risk patients over time.

Immunotherapy checkpoint inhibitors have changed the landscape of oncology treatment, however, they can come with a risk of adverse effects and, in rare cases, cause serious medical problems.

With the increasing use of these treatments in the oncology space, pharmacists should be knowledgeable about how to best manage patients on immunotherapy.

What if there was a drug delivery system intuitive enough to respond to changes in a patient’s disease?

An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.

Combination of azacitidine and nivolumab shows efficacy in patients with an average of 2 prior treatments for relapsed or refractory AML.

As biosimilar development continues to grow, pharmacists will be essential in transitioning both clinicians and patients alike in the use of these therapies.

Phase 2 data show positive results for a therapy including 2 immune checkpoint inhibitors and chemotherapy.

Amifampridine is an oral, nonspecific, voltage-dependent, potassium channel blocker that causes depolarization of a presynaptic membrane and slows or inhibits repolarization.

A phase 2 study demonstrated promising response rates and overall survival in patients with acute myeloid leukemia who were treated with azacitidine plus nivolumab.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018, thus far.

CVS Health announced that it has closed its acquisition of Aetna with the promise to transform the consumer health experience.

CVS Health announced that it has finalized its acquisition of Aetna with the promise to transform the consumer health experience.

Fostemsavir (ViiV Healthcare) may be a potential new option for patients with HIV who have become resistant to other medications.

New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.